ALEXANDRIA, Va., June 3 -- Array BioPharma, Boulder, Colorado, has been assigned a patent (No. 10,669,269, initially filed Sept. 27, 2017) by 13 co-inventors for "substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors." The co-inventors are Mark Laurence Boys, Boulder, Colorado, Robert Kirk DeLisle, Lyons, Colorado, Erik James Hicken, Boulder, Colorado, Aprl L. Kennedy, Denver, Colorado, David A. Mareska, McMurray, Pennsylvan . . .